Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARK3 | P27448 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
| ▸ | RARG | P13631 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490723 | 0.83 | MPI (0.30) | MPITDP1 | |
| SCHEMBL2488278 | 0.82 | TDP1 (0.56) | MPITDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL21218098 | 0.81 | MARK3 (0.36) | MARK3SMN1; SMN2PGRSLC9A1ALDH1A1 | |
| SCHEMBL5010350 | 0.80 | ALDH1A1 (0.39) | MARK3SMN1; SMN2PGRSLC9A1ALDH1A1 | |
| SCHEMBL15577510 | 0.80 | CYP19A1 (0.38) | MARK3SMN1; SMN2PGRSLC9A1ALDH1A1 | |
| SCHEMBL4506332 | 0.79 | SMN1; SMN2 (0.33) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL4950174 | 0.77 | MPI (0.45) | MPITDP1MEN1KMT2A | |
| SCHEMBL20105148 | 0.77 | SLC6A4 (0.39) | MARK3SMN1; SMN2ALDH1A1SLC6A4SLC6A2 | |
| SCHEMBL17254682 | 0.77 | SLC6A4 (0.39) | MARK3SMN1; SMN2ALDH1A1SLC6A4SLC6A2 | |
| SCHEMBL16707142 | 0.77 | BRD4 (0.40) | BRD4SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291968-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | GEORGES GUY | 2009-11-26 | — | — | US | disclosed |
| EP-2001882-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-La Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| US-7462639-B2 | e.g 3-(7,7-Dimethyl-6-oxo-1,5,6,7-tetrahydro-imidazo[4,5-f]indol-2-yl)-1H-pyrazol-4-yl]-carbamic acid benzyl ester; Aurora A (serotonin/threonine) kinase inhibitors; anticarcinogenic agent; colorectal, breast, lung, prostate, pancreatic, gastric, bladder, ovarian cancer, melanoma, neuroblastoma | HOFFMANN-LA ROCHE INC. (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1885725-B1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | EP | disclosed |
| CN-101160312-A | Tricyclic azole derivatives, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | CN | disclosed |
| EP-1885725-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-02-13 | — | — | EP | disclosed |
| EP-1879894-A1 | AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| CN-101080408-A | Trycyclic heterocycles, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-11-28 | — | — | CN | disclosed |
| US-7285569-B2 | Tricycles, their manufacture and use as pharmaceutical agents | HOFF HOFFMANN-LA ROCHE INC. (US) | 2007-10-23 | — | — | US | disclosed |
| WO-2007107346-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| EP-1831224-A2 | TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| EP-1793822-A1 | TRICYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| US-20060235065-A1 | Aminopyrazole derivatives | HOFFMANN-LA ROCHE INC. | 2006-10-19 | — | — | US | disclosed |
| WO-2006108488-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108489-A1 | AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| US-20060235013-A1 | Tricyclic azole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | US | disclosed |
| US-20060142247-A1 | Tricyclic heterocycles | HOFFMANN-LA ROCHE INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006063841-A2 | TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006032519-A1 | TRICYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-30 | — | — | WO | disclosed |
| US-20060069145-A1 | Tricycles, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291968-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | CYP3A43, CYP3A5, CYP3A7 | MARK3 814/4885SMN1; SMN2 4281/4885PGR 1475/4885 |
| US-20060235013-A1 | Tricyclic azole derivatives | CYP3A5, CYP3A43, CYP11B1 | MARK3 2981/4885SMN1; SMN2 3734/4885PGR 1521/4885 |
| US-20060235065-A1 | Aminopyrazole derivatives | CYP3A43, CYP3A5, CYP3A4 | MARK3 701/4885SMN1; SMN2 3516/4885PGR 3413/4885 |
| US-20060069145-A1 | Tricycles, their manufacture and use as pharmaceutical agents | ABCB1, CYP3A43, CYP3A5 | MARK3 4282/4885SMN1; SMN2 3901/4885PGR 2112/4885 |
| US-20060142247-A1 | Tricyclic heterocycles | CYP11B1, CYP11B2, CYP3A43 | MARK3 4176/4885SMN1; SMN2 1869/4885PGR 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.